[Abstract 11040] A collaborative, peer-based experience to support meaningful professional development in the evolving standards of care for HER2+ metastatic breast cancer

Presented at the American Society of Clinical Oncology 2022 Annual Meeting, June 3 - 7, 2022.

Authors

Latha Shivakumar, PhD¹; Rukiya Wongus¹; Steven Haimowitz, MD²; Lisa Shah, PhD², Amanda Ye, RPh, PharmD²; and Leigh Boehmer, PharmD, BCOP¹

¹Association of Community Cancer Centers, ²RealCME, a HealthCourse Company

Background

Although the COVID-19 pandemic quickly created a spotlight on distance learning, identifying models that can deliver effective educational programs and best serve the needs of oncology clinicians remains a significant challenge. We report outcomes from a CME program on the evolving standards of care for advanced HER2+ breast cancer presented on the novel digital platform, Gather-ed. Gather-ed offers a personalized social learning experience that prioritizes engagement, peer-to-peer learning, and mentorship within a small group setting. Over the course of several weeks, 87 learners progressed individually through self-study modules, but collaboratively through asynchronous group challenges and synchronous live group discussions.

Methodology

• Learner participation and engagement data were used to conduct quantitative analysis
• Thematic analysis was conducted using NVivo qualitative analytical software

Conclusions

• 87 highly-qualified providers engaged in a CME program  on HER2+ breast cancer on a social learning platform.
• Engagement levels were high, with an average of 6 platform interactions per learner.
• Feedback demonstrated strong impact of the live group discussions on learners’ intended practice changes.
• Analysis of collaborative group challenges and live group discussions demonstrated impact on learners’ views on treatment guidelines.
• Overall, the outcomes from this analysis highlight the utility of the Gather-ed platform in supporting meaningful professional development for providers who treat patients with advanced HER2+ breast cancer.